Hepatocyte growth factor in blood and gastric cancer risk: a nested case-control study.
Potential of hepatocyte growth factor (HGF) stimulating signaling pathways related to cytotoxin-associated gene A (CagA) to predict GC development has not been fully investigated. We conducted a nested case-control study consisting of 238 GC cases and 238 matched controls within the Korean Multicenter Cancer Cohort. Plasma HGF concentrations were measured with a human HGF enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) for GC development according to HGF level were calculated using conditional logistic regression model. Sequential elevation of GC risk according to HGF level increase was observed (OR, 10.99; 95% CI, 4.91-24.62 for highest quartile HGF (≥364 pg/mL) vs. lowest quartile HGF (<167 pg/mL). A significantly increased GC risk associated with high HGF level measured even 6 or more years prior to cancer diagnosis was also found. Group with both high risk of HGF and CagA-related genetic variants was associated with highest GC risk compared to group with both low risk of HGF and genetic variants (p-interaction = 0.05). Model performance including HGF and CagA-related genetic variants to discriminate GC was fair (area under the curve of receiver operating characteristic (AUC-ROC), 0.71; 95% CI, 0.64-0.78) and significantly higher than that of model not including those biomarkers. Our results suggest HGF as a potential biomarker to predict GC development. These findings suggest HGF as a useful biomarker to predict GC risk. Further research to assess GC risk based on useful biomarkers including HGF may contribute to primary prevention of GC.